clofazimine has been researched along with Disease, Pulmonary in 9 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clofazimine (CFZ) is used to treat pulmonary non-tuberculous mycobacterial (NTM) infection; however, its pharmacokinetics remain unexplored in patients with pulmonary NTM, and the relationship between CFZ serum concentration and adverse effects has not been investigated." | 1.72 | Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection. ( Fujiwara, K; Furuuchi, K; Hanada, K; Hiramatsu, M; Kurashima, A; Morimoto, K; Ohta, K; Shiraishi, Y; Uesugi, F; Watanabe, F; Yoshiyama, T, 2022) |
| "Oral clofazimine was added in cases of (1) M abscessus subspecies abscessus (here M abscessus) or (2) M abscessus subspecies massiliense (here M massiliense) with cavitary lesions." | 1.62 | Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease. ( Daley, CL; Huh, HJ; Jeon, K; Jhun, BW; Kang, N; Kim, H; Koh, WJ; Kwon, OJ; Lee, NY, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Watanabe, F | 1 |
| Furuuchi, K | 1 |
| Hanada, K | 1 |
| Fujiwara, K | 1 |
| Uesugi, F | 1 |
| Hiramatsu, M | 1 |
| Yoshiyama, T | 1 |
| Shiraishi, Y | 1 |
| Kurashima, A | 1 |
| Ohta, K | 1 |
| Morimoto, K | 1 |
| Sriram, D | 1 |
| Wahi, R | 1 |
| Maggioncalda, EC | 1 |
| Panthi, CM | 1 |
| Lamichhane, G | 1 |
| Park, YE | 1 |
| Chong, YP | 1 |
| Lee, HJ | 1 |
| Shim, TS | 2 |
| Jo, KW | 2 |
| Kang, N | 1 |
| Jeon, K | 2 |
| Kim, H | 1 |
| Kwon, OJ | 1 |
| Huh, HJ | 1 |
| Lee, NY | 1 |
| Daley, CL | 2 |
| Koh, WJ | 2 |
| Jhun, BW | 2 |
| Yang, B | 1 |
| Moon, SM | 1 |
| Lee, H | 1 |
| Park, HY | 1 |
| Kim, DH | 1 |
| Kim, SY | 1 |
| Shin, SJ | 1 |
| Lee, SFK | 1 |
| Laughon, BE | 1 |
| McHugh, TD | 1 |
| Lipman, M | 1 |
| Kim, S | 1 |
| Lee, JY | 1 |
| Lee, SD | 1 |
| Kim, WS | 1 |
| Kim, DS | 1 |
| Field, SK | 1 |
| Cowie, RL | 1 |
| Zaugg, M | 1 |
| Salfinger, M | 1 |
| Opravil, M | 1 |
| Lüthy, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identification of Host Susceptibility Factors and Development of Biomarkers for Diagnosis, Prognosis and Treatment of Nontuberculous Mycobacterial Lung Disease[NCT00970801] | 300 participants (Anticipated) | Observational | 2008-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for clofazimine and Disease, Pulmonary
| Article | Year |
|---|---|
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculo | 2019 |
Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Clofazim | 1993 |
7 other studies available for clofazimine and Disease, Pulmonary
| Article | Year |
|---|---|
Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection.
Topics: Clofazimine; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Diseases; Nontuberculous | 2022 |
Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice.
Topics: Anti-Bacterial Agents; Clofazimine; Humans; Lung Diseases; Microbial Sensitivity Tests; Mycobacteriu | 2022 |
Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.
Topics: Anti-Bacterial Agents; Clofazimine; Humans; Lung Diseases; Moxifloxacin; Mycobacterium avium Complex | 2022 |
Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease.
Topics: Administration, Inhalation; Aged; Amikacin; Anti-Bacterial Agents; Azithromycin; Clofazimine; Drug T | 2021 |
Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease.
Topics: Clofazimine; Drug Therapy, Combination; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium ab | 2017 |
Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy.
Topics: Aged; Anti-Bacterial Agents; Clofazimine; Drug Therapy, Combination; Female; Fluoroquinolones; Human | 2014 |
Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine.
Topics: Aged; Aged, 80 and over; Antitubercular Agents; Clofazimine; Drug Therapy, Combination; Ethambutol; | 2003 |